EPIDUO

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Japan, Lithuania, Malta, New Zealand, Poland, Romania, Singapore, Spain, Tunisia, UK.

Active ingredients

The drug EPIDUO contains a combination of these active pharmaceutical ingredients (APIs):

1	Adapalene UNII 1L4806J2QF - ADAPALENE
	Adapalene is a retinoid-like compound which in, in vivo and in vitro models of inflammation, has been demonstrated to possess anti-inflammatory properties. Mechanically, adapalene binds like tretinoin to specific retinoic acid nuclear receptors but, unlike tretinoin not to cytosolic receptor binding proteins. Adapalene is used in the treatment of acne and is also used (off-label) to treat keratosis pilaris as well as other skin conditions.
	Read more about Adapalene
2	Benzoyl peroxide UNII W9WZN9A0GM - BENZOYL PEROXIDE
	Benzoyl peroxide is a highly lipophilic, oxidising agent with keratolytic and bacteriocidal effects. The effectiveness of benzoyl peroxide in the treatment of acne vulgaris is primarily attributable to its antibacterial activity, especially with respect to Propionibacterium acnes. Benzoyl peroxide is also believed to be effective in the treatment of acne on account of its anti-inflammatory and mild keratolytic properties.
	Read more about Benzoyl peroxide

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
EPIDUO Gel	MPI, EU: SmPC	Medicines and Medical Devices Safety Authority (NZ)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
D10AD53	Adapalene, combinations	D Dermatologicals → D10 Anti-acne preparations → D10A Anti-acne preparations for topical use → D10AD Retinoids for topical use in acne
Discover more medicines within D10AD53

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	8954G, 8955H
BR	Câmara de Regulação do Mercado de Medicamentos	510102001171319, 510102003172312
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	29314-07-10, 3280-MEE-0618
EE	Ravimiamet	1731877, 1731888, 1731899, 1731901, 1731912, 1731923
ES	Centro de información online de medicamentos de la AEMPS	69445, 81359
FI	Lääkealan turvallisuus- ja kehittämiskeskus	029839, 114687, 114698, 386977, 408675, 491468
FR	Base de données publique des médicaments	60972530, 64950392
GB	Medicines & Healthcare Products Regulatory Agency	243938, 380227
HK	Department of Health Drug Office	58988, 66483
HR	Agencija za lijekove i medicinske proizvode	HR-H-671525095, HR-H-673699134
IE	Health Products Regulatory Authority	21002
IL	מִשְׂרַד הַבְּרִיאוּת	8943, 9374
JP	医薬品医療機器総合機構	2699805Q1020
LT	Valstybinė vaistų kontrolės tarnyba	1082748, 1082749, 1082750, 1082751, 1082752, 1082753, 1082754, 1082755, 1082756, 1082757
MT	Medicines Authority	MA117/01202, MA117/01203
NZ	Medicines and Medical Devices Safety Authority	14153
PL	Rejestru Produktów Leczniczych	100192249, 100377380
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W63540001, W63540002, W63540003, W63540004, W63540005, W63540006, W63540007, W63540008, W63540009, W63540010, W69284001, W69284002, W69284003, W69284004, W69284005, W69284006, W69284007, W69284008, W69284009, W69284010
SG	Health Sciences Authority	13789P, 15460P
TN	Direction de la Pharmacie et du Médicament	7393091, 7393111
US	FDA, National Drug Code	0299-5906, 0299-5908